PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
17.22%
Revenue growth 1.25-1.5x AVGO's 11.69%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
31.76%
Gross profit growth at 50-75% of AVGO's 43.88%. Martin Whitman would question if cost structure or brand is lagging.
80.61%
EBIT growth below 50% of AVGO's 318.18%. Michael Burry would suspect deeper competitive or cost structure issues.
122.45%
Operating income growth under 50% of AVGO's 318.18%. Michael Burry would be concerned about deeper cost or sales issues.
106.92%
Net income growth comparable to AVGO's 106.45%. Walter Schloss might see both following similar market or cost trajectories.
104.76%
EPS growth similar to AVGO's 106.90%. Walter Schloss would assume both have parallel share structures and profit trends.
110.00%
Similar diluted EPS growth to AVGO's 106.90%. Walter Schloss might see standard sector or cyclical influences on both firms.
-0.95%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.31%
Reduced diluted shares while AVGO is at 1.87%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.23%
Dividend growth of 0.23% while AVGO is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
49.73%
Positive OCF growth while AVGO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
19.45%
Positive FCF growth while AVGO is negative. John Neff would see a strong competitive edge in net cash generation.
61.72%
Positive 10Y revenue/share CAGR while AVGO is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
22.16%
Positive 5Y CAGR while AVGO is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
-8.11%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
110.74%
Positive long-term OCF/share growth while AVGO is negative. John Neff would see a structural advantage in sustained cash generation.
22.04%
Positive OCF/share growth while AVGO is negative. John Neff might see a comparative advantage in operational cash viability.
138.85%
Positive 3Y OCF/share CAGR while AVGO is negative. John Neff might see a big short-term edge in operational efficiency.
79.23%
Positive 10Y CAGR while AVGO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
31.73%
Positive 5Y CAGR while AVGO is negative. John Neff might view this as a strong mid-term relative advantage.
-8.03%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
59.53%
Equity/share CAGR of 59.53% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
0.89%
Equity/share CAGR of 0.89% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-5.83%
Negative 3Y equity/share growth while AVGO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
460.05%
Dividend/share CAGR of 460.05% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
428.42%
Dividend/share CAGR of 428.42% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
260.00%
3Y dividend/share CAGR of 260.00% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
15.35%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
4.99%
Inventory growth well above AVGO's 1.32%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.41%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.42%
BV/share growth above 1.5x AVGO's 0.47%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
-0.27%
Our R&D shrinks while AVGO invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.98%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.